

NeuroQTM



Quantitative Analysis for Neuroimaging Technology

Display and Analysis Program Version 3.8

Operator Guide



Copyrights, Trademarks, Restrictions

© Copyright 2005-2018, by Syntermed, Inc. All rights reserved. Revision 17, Published 2018 Printed in the United States of America Syntermed reserves the right to modify the design and specifications contained herein without prior notice. Please contact your local Sales Representative for the most current information. No part of this documentation may be reproduced or transmitted in any form by any means, electronic or mechanical, without written permission of Syntermed. NeuroQTM is a registered trademark of Syntermed, Inc.

Insight Segmentation and Registration Toolkit (ITK), Copyright (c) 1999-2008 Insight Software Consortium, All rights reserved.

Indication	The NeuroQ TM $3.5 - 3.8$ program is used to regionally quantify activity in brain PET
	and SPECT scans using a ROI count method. It displays co-registered PET, SPECT
	and CT images, along with output from quantification of activities reflecting regional
	concentrations of FDG, amyloid imaging agents, SPECT perfusion and dopamine
	transporter radiotracers, relative to activities in any of several user-selected reference
	regions or whole brain. It provides for displaying and quantifying the regional
	differences between two PET or SPECT brain studies for the same patient, or the levels
	of amyloid imaging agents retained in specified brain regions of a patient, and for
	assisting the user in the examination of brain scans acquired for assessing differential
	diagnosis of neurodegenerative processes underlying symptoms of cognitive and
	movement disorders by comparing regional activity values to each other and to those in
	brain scans acquired for asymptomatic control subjects. These neurodegenerative
	processes can be Alzheimer's disease, Lewy body dementia, Parkinson's disease with
	dementia, vascular dementia, and frontotemporal dementia.
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation of the PET brain scan, and quantitative results, prior to
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation of the PET brain scan, and quantitative results, prior to making his final interpretation. This comprehensive processing technique (as with all
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation of the PET brain scan, and quantitative results, prior to making his final interpretation. This comprehensive processing technique (as with all diagnostic imaging) is not perfect, and will be associated with some false positive and
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation. This comprehensive processing technique (as with all diagnostic imaging) is not perfect, and will be associated with some false positive and false negative results. This program has no direct adverse effect on health since the
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation. This comprehensive processing technique (as with all diagnostic imaging) is not perfect, and will be associated with some false positive and false negative results. This program has no direct adverse effect on health since the results represent only a part of the information, which the physician will utilize for his
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation. This comprehensive processing technique (as with all diagnostic imaging) is not perfect, and will be associated with some false positive and false negative results. This program has no direct adverse effect on health since the results represent only a part of the information, which the physician will utilize for his final interpretation. The final responsibility for interpretation of the study lies with the
Warning	The product is intended for use by trained nuclear technicians and nuclear medicine physicians. The clinician remains ultimately responsible for the final interpretation and diagnosis based on standard practices and visual interpretation of all SPECT and PET data. This program serves merely as a display and processing program to aid in the diagnostic interpretation of a patient's study. It was not meant to replace or eliminate the standard visual analysis of the PET brain scan. The physician should integrate all of the patients' clinical and diagnostic information, i.e. patients' history, quality control images, visual interpretation. This comprehensive processing technique (as with all diagnostic imaging) is not perfect, and will be associated with some false positive and false negative results. This program has no direct adverse effect on health since the results represent only a part of the information, which the physician will utilize for his final interpretation. The final responsibility for interpretation of the study lies with the physician.

NeuroQ General Statement

Accuracy	The sensitivity and specificity associated with this medical device and this accuracy is published in peer review medical journals. The program is used as an adjunct or additional tool that the physician can use to integrate the output into his clinical interpretation of the study. The initial validation used 44 patients, 26 were documented by clinical longitudinal follow-up to have progressive dementia and 18 were documented by clinical longitudinal follow-up to have a non-progressive course. In this study which compared expert visual interpretation to NeuroQ the sensitivity was 80% for visual and 81% for NeuroQ (1). The specificity was 89% for visual and 93% for NeuroQ. In another study comparing visual to NeuroQ in a separate set of 68 patients the sensitivity was 84% and specificity 94% for NeuroQ with an accuracy of 87% (1). It is our contention that this accuracy will not be changed significantly in the current populations. We continue to perform validation through our testing method by insuring that the output values obtained in a subset of patients used in our testing remain within 1% of the original results which insures that we would obtain the same accuracy in the clinical population that was used previously.
Help/About	The version number and Global Unique Device Identification Database (GUDID) information can be located within the NeuroQ application by going to the Help/About section in the program.
Installation	The installation instructions can be found on our website: https://www.syntermed.com/client password: Client123. Click on the NeuroQ link and open up the NeuroQ Installation Guide document for the instructions. Syntermed will also assist in installation and training remotely via the web. Syntermed can be reached at 888-263-4446 ext. 1.
Rx Statement	<u>Caution: Federal law restricts this device to sale by or on the order of a physician.</u> The NeuroQ application is to be used for the analysis of PET and SPECT brain images produced from brain imaging radiopharmaceuticals. There are no contraindications or adverse reactions associated with this device. Warnings and precautions for the use of this device are described in this user manual.
Hardware Specifications	 Minimum: MS Windows 7 SP1 (32 or 64 bit), core i3/i5, 4Gb of RAM and a 24" 1080p monitor Recommended: MS Windows 7 SP1 (64 bit), core i7, SSD, 8Gb of RAM and a 24" 1920x1200 monitor. NeuroQ requires a horizontal resolution of at least 1280 (i.e. 1920x1200 monitor used in portrait mode is not recommended). Note: While systems not meeting the minimum requirements may run, your experience will be better when meeting or exceeding the recommended list.
Cybersecurity	The risks associated with cybersecurity and the NeuroQ [™] medical device have been ass resolved to a satisfactory level. The risks are associated with the files or images being con a security breach. There are methods in place to prevent this corruption through MD5 ch encryption, multiple patient labels on output screens to allow for patient authentication by using methods for compiling of code and interfaces that substantially reduce or eliminate to corrupt the code. In addition, it is the responsibility of the local information technology at the institution to implement the necessary security methods and procedures to restrict the computers and data stored on these systems. Some of these methods include limiting trusted users through user ID and passwords, implementing timed methods to terminate and using strengthen password protection methods. They should also ensure trusted co implement methods for detection of security compromises and for retention and recovery.



	New software versions as well as patches are compiled and moved to a known clean com are checked there for viruses and malware. Software is then packaged together into a which is signed with a key to ensure the installer remains intact throughout testing a distribution.
	Validated software updates and patches are provided at least annually and whenever a cyb risk is identified. Notification of availability of these patches is made through the itself. These updates are delivered as signed installers that present signature information t to confirm validity of the source of the patch.
	It is always recommended that the installation environment have adequate, updated anti- anti-malware scanners in place. It is also recommended that a firewall, by default, deny a and outbound traffic on the network. At installation time, a list of ports and destinations for exceptions is provided specific to each installation.
Authorized	Medical Device Safety Service GmbH (MDSS)
Representative	Schiffgraben 41, 30175 Hannover, Germany



Table of Contents

PROGRAM DESCRIPTION	6
PROCESSING	8
NEUROQ TM QUALITY CONTROL SCREEN	9
NEUROQ TM ANALYSIS SCREEN (LEFT SIDE)	
NEUROQ TM DISPLAY SCREEN (RIGHT SIDE)	
NEUROOTM COMPARE DISPLAY SCREEN	
NEUROOTM PET/CT DISPLAY SCREEN	
EQUAL TM ANALYSIS	
CONTROL DATABASE	
AMYLOID OVERVIEW, PROCESSING, AND DISPLAY	
SPECT OVERVIEW, PROCESSING AND DISPLAY	
3D DISPLAY	
Analysis of Basal Ganglia Structures	40
REFERENCES RELATED TO NEUROOTM DEVELOPMENT	44



Quantitative Analysis for Neuroimaging Technology Version 3.8

Overview

The **NeuroQTM** Display and Analysis Program has been developed to aid in the assessment of human brain scans through quantification of mean pixel values lying within standardized regions of interest, and to provide quantified comparisons with brain scans derived from FDG-PET or HMPAO SPECT studies of defined groups having no identified neuropsychiatric disease or symptoms, i.e., asymptomatic controls (AC). The Program provides automated analysis of brain PET and SPECT scans, with output that includes quantification of relative activity in 240 different brain regions, as well as measures of the magnitude and statistical significance with which activity in each region differs from mean activity values of brain regions in the AC database. In addition, the program includes NeuroQTM Quality Control Screen, PET/CT display screen, patient study comparison analysis, amyloid analysis and EQuALTM a tool for evaluating temporal lobe Epilepsy, PET/MR display screen, saving the cluster screen, remembering display settings, auto processing, and ability for the user to generate their own normal limit and use within the NeuroQTM application. The new features of version 3.8 include a quantitative analysis of basal ganglia analysis. This manual describes the display and analysis features of the program, and their end-user operation.

Program Description

The NeuroQ[™] Program is indicated to:

- 1) Assist with regional assessment of human brain scans, through automated quantification of mean pixel values lying within standardized regions of interest (S-ROI's).
- 2) Assist with comparisons of the activity in brain regions of individual scans relative to normal activity values found for brain regions in FDG-PET scans, through quantitative and statistical comparisons of S-ROI's.
- 3) Compare activity in brain regions of individual scans between two studies from the same patient.
- 4) Compare activity between symmetric regions of interest within the brain PET study.
- 5) Perform an image fusion of the patients PET and CT data.
- 6) Provide analysis of amyloid uptake levels in the brain.
- 7) Provide analysis of basal ganglia analysis.

The program requires the operator to select the patient's FDG or HMPAO SPECT Brain scan. Following a number of internal checks on the data (e.g., accurate radiopharmaceutical), for FDG, the operator has to initiate the quality control sequence which includes setting the reference line over the brain, perform a scalp correction on the data, subject the data to rigid registration to correct for brain tilt, and perform elastic spatial reformatting or normalization of the patient's scan into a standardized volumetric space. Following this step, the program determines the uptake in 240 ROIs, normalized to the uptake in the subject's sensorimotor cortical region (S-

CONFIDENTIAL



ROI). The uptake in the ROIs is then compared to a normal data base of uptakes, based upon uptake in the corresponding S-ROIs determined in 50 normal subjects without identified neuropsychiatric disease. Any region with an uptake below 1.65 S.D of the mean, established from the normal data base is considered abnormal as defined by falling within the lowest 5% of a normal distribution, with respect to regionally quantified control data*.

* (or the highest 5% of a normal distribution, for those cases in which NeuroQ is being used to identify hyper- rather than hypo- activity of radiotracer).



Processing

The FDG PET or HMPAO SPECT files in DICOM format need to be selected and imported into the NeuroQTM program. Once this is done the initial NeuroQTM Quality Control Screen will be displayed.

1) Note: when the study is first launched the Database in use should list the appropriate database for the patient selected. If the database is incorrect then go to the Control Database menu item and select the proper normal limit database before proceeding to the processing section.



2) Optimal processing requires that you perform the following steps for FDG-PET: set axial limits, perform scalp correction, and perform rigid registration. These processing steps are described below. Note: the QC is not performed for HMPAO SPECT studies.



Page 9 of 45

NeuroQ User Manual

	Neuro	О тм (Qualit	y Cont	rol Sci	reen				
e Processing Display Slice Display Reference Region Con	ntrol Database Meta	bolism Stu	dy Comparison	EQuAL						
atient Name: NeuroQ Demo (Case3 Abn Update)	Main	QC	Slices	Compare	PET/CT	EQuAL	bgQ	amyQ	3D	Save
Juy Date. 13-Aug-1330	Da	tabase in u	ıse: Default F	DG Database						
Set Axial Plane Limits		Remova	of Scalp Activit	у			Rigid Re	gistration		
↓ Upper Limit ↓ 23 ▲ Lower Limit ↓ 112	63	6	and a	Stor.			E	3	64	
Accent			Original			-	Refe	rence		
						3	6	13	E an	
		F	Processed 20				Ori	ginal		
	Accept		Threshold Process				Realigned	and Fused	Cq.	
					•		5	io 		•
					Refe	rence 💌	Ble	nd	Original	<u> </u>
							Rigid Re Reform	gistration nat PET		
					L A	ccept				

The Quality Control Screen is comprised of three sections: Set Axial Plane Limits, Removal of Scalp Activity, and Rigid Registration.

Set Axial Plane Limits



This feature allows the user to set the upper and lower limits for reconstruction by clicking the up and down arrows to move the lines. The limits can also be set by moving the cursor to a point on the image and click left to set the limit. The limits should be set so that only the brain images



are included in the reconstruction. When the limits are set to the proper location check the Accept box.



Removal of Scalp Activity

This feature allows for the removal of the scalp activity around the brain. In some cases there is excessive scalp activity which can interfere with the reformatting of the patients study to match the normal template. Move the slider bar to the desired threshold and then click on the Process button. It is recommended that the scalp correction be applied to every study and use 20 as the setting. The processed images are shown in the bottom row. Triangulation is enabled on these images by clicking left on any image and it will show you the plane for that location on the other two images. When the images are processed for scalp correction the Accept box will be checked.



<u>Rigid Registration</u>



The Rigid Registration allows for applying additional registration prior to the reformatting process used in NeuroQ[™]. This additional registration is helpful in cases where the patients head has excessive tilt. It is recommended that rigid registration be applied to all studies prior to reformatting. The top row shows the normal template as the reference image the middle row are the patients images and the bottom row are the fused reference and patient images after realignment. Triangulation is enabled on these images by clicking left on any image and it will show you the plane for that location on the other two images. When the images are processed



the Accept check box will be checked. If all of these QC steps are performed then the recommended iterations for reformatting is 10. If the Reformat button is selected then the study will automatically be reformatted with 10 iterations.

3) The next step involves reformatting the patient's transaxial slices to fit the normal template transaxial slices. This is performed by selecting the Reformat PET (or SPECT) button. The registration algorithm used for reformatting of the patient's data is a robust spatial transformation method published by Henry Huang and Ed Hoffman, along with their collaborators. It was originally described in IEEE (Tai et al., *IEEE Trans. Nucl. Sci. NS-44* 1997; **4**: 1606-1612.)



Note: in some cases the user may want to use a different number of iterations. This is performed from the Processing menu item and select Reformat from the drop down box as shown above.

4) For the most standard use of the Program (i.e., comparing an individual scan from the end-user's site to NeuroQTM 's built-in database), if all of the QC processing is performed as described in the previous section then it is recommended to use 10 iterations, and this is the only option that normally will ever need to be selected. The other choices in the Iterations pull-down menu (1, 2, 5, 15 and 20) have been retained in order to allow flexibility to use the tool in other ways: for example, 1) rapid testing of software operability by selecting a small number of iterations, 2) processing a batch of scans acquired at the end-user's site to create a new database with whatever number of iterations is desired, 3) sequential use of the reiteration routine, such as adding another 5 iterations to a scan that had already been reiterated 20 times in order to obtain a closer spatial fit in a case where the individual's original



scan is structurally very different from the normal template scan, 4) various research applications, etc.

5) Once the Reformat button has been selected, an information box will be displayed informing you of the number of iterations you have selected.



- 6) Click on the OK button and the patient's study will be reformatted to align with the normal template. On a current processor (core i7) the reformatting will take approximately 1 minute.
- 7) Once the study is reformatted the final quantitative analysis output will be displayed which is shown below.



ate: 15-A	Aug-1996	Cases Abn (opuate)	iviai()		ces Compare	PEI/CI	EQuAL	bgQ	amyQ	3D	Sav
: Demo3	3	Serie	s Desc: Unknown		Control a	nd patient values are norma	alized to the		Databas	e in use: Defa	ult FDG Da	atabase
G		Refer	rring Physician: Unkr	iown	average	pixel value among all region	is in each scan.		Normal	Template with	h Cluster R	legions
	25	LR	Rain C							Ø	3	0
	23	<u>y</u>	•	22	Refo	• O	ions; 10)	6	D	G)	
	Ĩ	+ 4		Ĩ	•				22	24		32
ain	-	FDG-I	Brain-Normal	-					-	100	w	-
Metabolic I	Regions:									6.0	2	6.
	Region	Mean AC	SD AC	Patient (Pt)	Pt-M(AC)	#SD from M(AC)		- 81		1000	N 3	(China)
45	rAVC.p30	1.0068	0.0336	0.6360	-0.3707	-11.0236			1.9	19.52		12 37
46	IAVC.p30	1.0610	0.0397	0.8559	-0.2051	-5.1677			88 B (1.02	12	N F N
47	rsLT.p30	1.0837	0.0358	0.8474	-0.2363	-6.5942			Sec.			
48	IsLT.p30	1.0900	0.0416	0.9369	-0.1531	-3.6777			34	35		36
49	IsLT.p32	1.1303	0.0314	1.0356	-0.0947	-3.0159		1.11	100	1872.37		143
50	rAVC.p32	1.0364	0.0471	0.6041	-0.4322	-9.1735		3.4		10.000	6.5.1	- C 201
			0.0300	0.8871	-0.1965	-6.5467		1.40	100		~	
51	rsLT.p32	1.0836			0 1104				Contraction of the			
51 52	rsLT.p32 rsLT.p34	1.0836	0.0227	0.9530	-0.1104	-5.1256						5 1 1
51 52 53	rsLT.p32 rsLT.p34 rAVC.p34	1.0836 1.0694 1.0378	0.0227 0.0365	0.9530	-0.4489	-5.1256		- 16	U .7	(\bigcirc)		100
51 52 53 54	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36	1.0836 1.0694 1.0378 1.0801	0.0227 0.0365 0.0601	0.9530 0.5890 0.5761	-0.1164 -0.4489 -0.5039	-5.1256 -12.3139 -8.3862		- 20	.			. ,
51 52 53 54 55	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 IAVC.p36	1.0836 1.0694 1.0378 1.0801 1.0489	0.0227 0.0365 0.0601 0.0642	0.9530 0.5890 0.5761 0.8531	-0.1164 -0.4489 -0.5039 -0.1959	-5.1256 -12.3139 -8.3862 -3.0505		N	1			6
51 52 53 54 55	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 IAVC.p36 <	1.0836 1.0694 1.0378 1.0801 1.0489	0.0227 0.0365 0.0601 0.0642	0.9530 0.5890 0.5761 0.8531	-0.1164 -0.4489 -0.5039 -0.1959	5.1256 12.3139 -8.3862 3.0505 ¥		A	42	46		52
51 52 53 54 55 er Regions	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 IAVC.p36 <	1.0836 1.0694 1.0378 1.0801 1.0489	0.0227 0.0365 0.0601 0.0642	0.9530 0.5890 0.5761 0.8531	-0.1164 -0.4489 -0.5039 -0.1959	-5.1256 -12.3139 -8.3862 -3.0505 V		R	42 egional Hype	46 ometabolism		52
51 52 53 54 55 er Regions	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 IAVC.p36 < C B: Region	1.0836 1.0694 1.0378 1.0801 1.0489 Mean AC	0.0227 0.0365 0.0601 0.0642	0.9530 0.5890 0.5761 0.8531 Patient (Pt)	-0.1164 -0.4489 -0.5039 -0.1959	-5.1256 -12.3139 -8.3862 -3.0505 * * * * * * * * * * * * *		Roi Name	42 egional Hype	46 ometabolism		52
51 52 53 54 55 er Regions	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 iAVC.p36 < C Region rGFs	1.0836 1.0694 1.0378 1.0801 1.0489 Mean AC 1.0094	0.0227 0.0365 0.0601 0.0642 SD AC 0.0533	0.9530 0.5890 0.5761 0.8531 Patient (Pt) 1.0161	-0.1164 -0.4489 -0.5039 -0.1959 Pt-M(AC) 0.0067	-5.1256 -12.3139 -8.3862 -3.0505 * * * * * * * * * * * * *		ROI Name Magnitud	42 egional Hype e: de of Difference	46 ometabolism ce:		52
51 52 53 54 55 er Regions 1 2	rsLT,p32 rsLT,p34 rAVC,p34 rAVC,p36 IAVC,p36 < Region rGFs rGFd	1.0836 1.0694 1.0378 1.0801 1.0489 	0.0227 0.0365 0.0601 0.0642 SD AC 0.0533 0.0375	0.9530 0.5890 0.5761 0.8531 Patient (Pt) 1.0161 1.1591	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.0067 -0.0067	-5.1256 -12.3139 -8.3862 -3.0505 V *SD from M(AC) 0.1258 A 2.4664		ROI Name Magnitud #SD from	42 egional Hypo e: de of Differenci n M(AC):	46 ometabolism ce:	<u>y</u>	52
51 52 53 54 55 er Regions 1 2 3	rsLT,p32 rsLT,p34 rAVC,p34 rAVC,p36 IAVC,p36 < Region rGFs rGFs IGFs	1.0836 1.0694 1.0378 1.0801 1.0489 Mean AC 1.0094 1.0666 0.9778	0.0227 0.0365 0.0601 0.0642 SD AC 0.0533 0.0375 0.0481	0.9530 0.5890 0.5761 0.8531 Patient (Pt) 1.0161 1.1591 1.0998	-0.1164 -0.4489 -0.5039 -0.1959 Pt-M(AC) 0.0067 0.0925 0.1220	-5.1256 -12.3139 -8.3862 -3.0505 V > #SD from M(AC) 0.1258 2.4664 2.5376		Ro ROI Name #SD from Positive(+	42 egional Hype e: de of Difference h M(AC):) sign correspond	46 ometabolism se: ds to values > Mea	an AC	52
51 52 53 54 55 er Regions 1 2 3 4	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 iAVC.p36 iAVC.p36 c c c c c c c c c c c c c c c c c c c	1.0836 1.0694 1.0378 1.0801 1.0489 <u>Mean AC</u> 1.0094 1.0666 0.9778 1.0552	0.0227 0.0365 0.0601 0.0642 SD AC 0.0533 0.0375 0.0481 0.0347	0.9530 0.5890 0.5761 0.8531 Patient (Pt) 1.0161 1.1591 1.0998 1.1020	-0.1164 -0.449 -0.5039 -0.1959 -0.1959 -0.0067 0.0925 0.1220 0.0468	-5.1256 -12.3139 -8.3862 -3.0505 > #SD from M(AC) 0.1258 2.4664 2.5376 1.3462		Ro ROI Name Magnitue #SD from Positive(+ Negative(42 egional Hype e: de of Difference n M(AC):) sign correspond -) sign correspond	46 ometabolism ce: ds to values > Mea ds to values < Mea	an AC an AC	52
51 52 53 54 55 er Regions 1 2 3 4 5	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 IAVC.p36 IAVC.p36 IAVC.p36 < < Region rGFs rGFd IGFs IGFd ISFd ISM	1.0836 1.0694 1.0378 1.0801 1.0489	0.0227 0.0365 0.0601 0.0642 0.0533 0.0375 0.0481 0.0347 0.0422	0.9530 0.5890 0.5761 0.8531 Patient (Pt) 1.0161 1.1591 1.0998 1.1020 1.0552	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.1959 -0.0067 -0.0925 -0.1220 -0.0468 -0.0060	-5.1256 -12.3139 -8.3862 -3.0505 × × #SD from M(AC) 0.1258 2.4664 2.5376 1.3482 -0.1423		Re ROI Nam #SD from Positive(+ Negative(REGIONAL	42 egional Hype e: de of Difference n M(AC):) sign correspond -) sign correspond -) sign correspond	46 ometabolism ce: ds to values > Mea ds to values < Mea R DATA	an AC an AC	52
51 52 53 54 55 er Regions 1 2 3 4 5 6	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 rAVC.p36 c rGFs rGFd IGFs IGFd IGFs IGFd ISM rSM	1.0836 1.0894 1.0378 1.0801 1.0489 Mean AC 1.0094 1.0686 0.9778 1.0552 1.0612 1.0612	0.0227 0.0365 0.0601 0.0642 SD AC 0.0533 0.0375 0.0481 0.0347 0.0481 0.0347	0.9530 0.5890 0.5761 0.8531 1.0161 1.0161 1.1591 1.0998 1.1020 1.0552 0.9428	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.0067 -0.0067 -0.0067 -0.0060 -0.1014	-5.1256 -12.3139 -8.3862 -3.0505 > #SD from M(AC) 0.1258 -2.4664 2.5376 1.3482 -0.1423 -3.0540		Re ROI Name #SD from Positive(+ Negative(REGIONAL reVC.p36 reAVC.p36	42 egional Hype e: de of Difference n M(AC): 9 sign correspon - AND CLUSTER 6 (Difference: -0	46 ometabolism se: ds to values > Mea ds to values < Mea ds to values < Mea D 5039) is the most	an AC an AC thypometabo	52 lic
51 52 53 54 55 er Regions 1 2 3 4 5 6 6 7	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p38 iAVC.p36 iAV	1.0836 1.0694 1.0378 1.0801 1.0489	0.0227 0.0365 0.0601 0.0642 0.0533 0.0375 0.0481 0.0347 0.0422 0.0332 0.0472	0.9530 0.5580 0.5761 0.8531 Patient (Pt) 1.0161 1.1591 1.0998 1.1020 1.0552 0.9428 0.9428	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.0067 -0.0925 -0.1220 -0.0060 -0.0060 -0.1014 -0.00643	-5.1256 -12.3139 -8.3862 -3.0505 > #SD from M(AC) 0.1258 2.4664 2.5376 1.3482 -0.1423 -3.0540 1.3627		Ret ROI Name Magnituu #SD from Positive(+ Negative(REGIONAL rAVC.p36 region. rAVC.p36	42 egional Hype e: de of Difference h ((AC):) sign correspon : sign correspon : AND CLUSTEF : (Difference: -0 : (#SD from M(A)	46 cometabolism ce: ds to values > Mea ds to values < Mea PADTA 2.5039) is the most C): -12.3139) is the	an AC an AC t hypometabo	52 lic n the
51 52 53 54 55 er Regions 1 2 3 4 5 6 6 7 8	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 AVC.p36	1.0836 1.0694 1.0378 1.0801 1.0489	0.0227 0.0365 0.0601 0.0642	0.9530 0.5590 0.5761 0.8531 1.0161 1.0161 1.0161 1.0591 1.0592 0.9428 0.9645 0.8645	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.0067 -0.0925 -0.0925 -0.0925 -0.0925 -0.0925 -0.0926 -0.0104 -0.0060 -0.1014 -0.0643 -0.0718	-5.1256 -12.3139 -8.3862 -3.0505 × × #SD from M(AC) 0.1258 -2.4664 2.5376 1.3482 -0.1423 -3.0540 1.3627 -1.5556		Re ROI Nam- Magnitud #SD from Positive(+ Negative(REGIONAL rAVC.p36 region. rAVC.p34 most sign	42 egional Hypo e: de of Difference h M(AC):) sign correspon AND CLUSTER (Difference: -0 (#SD from M(A iffcant hypomete	46 ometabolism se: ds to values > Mea ds to values < Mea to values < Values > (Mea to values > (an AC an AC t hypometabo	52 Iic In the
51 52 53 54 55 er Regions 1 2 3 4 5 6 6 7 7 8 9	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p34 rAVC.p36 vCC.p36 v	1.0836 1.0894 1.0378 1.0801 1.0489 <u>Mean AC</u> 1.0094 1.0489 <u>Mean AC</u> 1.0094 1.0666 0.9778 1.0552 1.0612 1.0442 0.9202 0.9696 1.1236	0.0227 0.0365 0.0661 0.0642	0.9530 0.5500 0.5761 0.8531 Patient (Pt) 1.0161 1.0591 1.1020 1.0552 0.9428 0.9845 0.8978 1.0396	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.0067 -0.0925 -0.0925 -0.0925 -0.0925 -0.0468 -0.0060 -0.1014 -0.0643 -0.0718 -0.0718	-5.1256 -12.3139 -8.3862 -3.0505 > > #SD from M(AC) 0.1258 2.4664 2.5376 1.3462 -0.1423 -0.1423 -0.1423 -3.0540 1.3627 -1.5556 -2.6795		Rd ROI Name Magnitue #50 from Positive(+ Negative(REGIONAL rAVC.p34 region. rAVC.p34	42 egional Hype e: de of Difference -) sign correspon -) sign correspon - AND CLUSTER - (Difference: -0 - (#SD from M(A) iffcant hyperator	46 cometabolism ce: ds to values > Mea ds to values > Mea ds to values > Mea Po39) is the most (): -12.3139) is the abolism.	an AC an AC thypometabo he region with	52 IIC II the
51 52 53 54 55 er Regions 1 1 2 3 4 5 6 6 7 8 9 9 10	rsLT.p32 rsLT.p34 rAVC.p34 rAVC.p36 ↓AVC.p36 < Region rG76 rG76 IG76	1.0336 1.0634 1.0378 1.0801 1.0489 1.0489 1.0094 1.0666 0.9778 1.0666 0.9778 1.0612 1.0442 0.9522 0.9696 0.9696 1.1236 1.1236	0.0227 0.0385 0.0661 0.0642 SD AC 0.0533 0.0375 0.0481 0.0347 0.0481 0.0347 0.0482 0.0347 0.0422 0.0442	0.9530 0.5580 0.5761 0.8531	-0.1164 -0.4489 -0.5039 -0.1959 -0.1959 -0.1959 -0.1959 -0.0067 -0.0925 -0.0925 -0.1020 -0.0468 -0.0060 -0.1014 -0.0718 -0.0840 -0.0840 -0.0840	-5.1256 -12.3139 -8.3862 -3.0505 -> #SD from M(AC) 0.1258 -2.4664 2.5376 1.3482 -0.1423 -3.0540 1.3482 -0.1423 -3.0540 1.3627 -1.5556 -2.6795 0.5452		Re ROI Name #SD from Positive(+ Negative(REGIONAL rAVC.p36 region. rAVC.p36 region. rAVC.p36 region.	42 egional Hype e: de of Different N(AC):) sign correspon) sign correspon) sign correspon) sign correspon) sign correspon (fifterence: - 0, (fSD from M(A) (fifterent hypometer erence: - 0.410 D from M(A2):	46 cometabolism ds to values > Mea ds to values < Mea 2039) is the most c): -12.3139) is th abolism. 1) is the most hypp. -16.3842) is the di	an AC an AC thypometabo he region with ometabolic clu	52 52 lic the uster.

The left side of the window contains the "NeuroQTM Analysis" screen and the right side contains the "NeuroQTM Display" screen. These displays are defined below.



NeuroQTM Analysis Screen (Left Side)



File Menu – this allows the user to print the current screen, save the current screen in various formats, save just the cluster screen in the same various formats, pop-out a new window that displays a table of the abnormal clusters along with the cluster screen, set preferences for the default language and the default database, access the data screen, access the help screen and quit from the application. The Options for the save screen formats are shown below. Note: The DICOM Screen Capture allows the data to be saved in a format acceptable by PACS systems.



	Print		: NeuroQ Demo	(Case3 Al
	Save Screen As	>	Dicom SC	
	Save Cluster Screen	>	BMP	5
	Abnormal Cluster Screen		JPEG	
	Preferences		TIFF	L
	Data		PNG	
	Help		PPM	121
	Quit		ALC: 417.00	100
-	Wit-199300 13	-	And the second second	10 million - 1

a. Example of the new pop-out window displaying the abnormal clusters along with the cluster screen. There are options to print and save this screen under the File menu.





Preferences				×
NeuroQ™ Analysis Version	3.75 [Build	d: 201	70519.1	51142]
Default Language: Englis	n 💌			
Default Database: Automa	tically Sele	ect the	Databa	se 🔻
Use the Alternate Color Tab	le: 🕫 No	0	Yes	
Apply	Cance	el		

b. Preferences Screen for setting the default language, the default database, and an option for using an alternate color table for the cluster screen colors (blue -> yellow instead of blue -> red) that may be useful for users with Blue/Red color blindness.

1	1	1		~
Close	Save Tables	Save All	Save Raw Regions	Save Compare Regions
Region	cps pe	r pixel	∕Whole B:	rain
rGFs.p9 rGFd.p9 lGFd.p9 lGFd.p9 rSM.p9 rSM.p9 rSM.p9 rSM.p1 lGFd.p11 lGFd.p11 lGFd.p11 lGFd.p11 lSM.p11 lSM.p11 lSM.p11 lSM.p11 lSM.p12 rSPL.p12 rSPL.p12 rSPL.p12 rSPL.p12 rSPL.p14 lGFd.p14 rGFm.p14 lGFd.p14 rGFm.p14 lGFs.p14 lGFs.p14 lGFs.p14 lGFs.p14 rGFs.p14 lGFs.p17 rGFs.p17 lGCa.p17 rGCa.p17 rGCm.p17 rGFm.p17 lGFm.p17	75 98 92 63 10 94 10 10 95 10 95 10 95 10 95 10 95 10 97 10 10 10 10 10 10 10 10 10 10 10 10 10	0.24300 4.46500 5.97200 2.89300 45.9100 1.83200 24.4700 09.3200 6.40700 97.5800 2.02200 12.2800 78.5100 6.82900 29.8700 4.64300 22.61800 97.0400 92.8400 20.6500 76.9500 7.36500 26.4800 1.13700 39.5800 26.4800 1.13700 39.5800 26.4800 1.13700 39.5800 26.4800 1.13700 39.5800 26.4800 1.13700 39.5800 26.4800 1.13700 39.5800 26.4800 1.13700 39.5800 2.5700 19.1500 13.5300 43.1400 76.0700 15.1300 2.90300	$egin{array}{cccc} 0.68325800\\ 0.89656800\\ 0.84329800\\ 0.57638600\\ 0.95252700\\ 0.85774100\\ 0.93300100\\ 1.0102800\\ 0.98794500\\ 0.99246200\\ 0.9974400\\ 0.9974400\\ 0.99958400\\ 0.87612900\\ 1.0129700\\ 0.87612900\\ 1.0129700\\ 0.88961400\\ 0.99526700\\ 0.1116700\\ 1.118800\\ 1.0259000\\ 0.92815600\\ 1.058700\\ 0.92815600\\ 1.051800\\ 1.0410800\\ 1.0710700\\ 1.0155700\\ 0.87693100\\ 1.1186000\\ 1.1186000\\ 0.11186000\\ 0.87693100\\ 0.87693100\\ 0.11186000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.889000\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.8800\\ 0.800\\ 0.880$	

Data – The data c. button will display the data screen which gives the "mean" (average number of counts per second per pixel in each ROI) for each of the 240 ROIs of the patient; "norm" refers to the "mean" normalized to the average of all pixels in all ROI's (default). This screen is shown below. This data can be saved and then imported into another application like Excel for further analysis. You have the option to "Save Tables", which are the tables presented on the Main screen for regions and clusters; "Save Raw Regions", which saves the raw information for the ROIs; or "Save All", which saves all of the available information.



()	NeuroQ™ Help	-		×						
NeuroQ™ An	alysis Version 3.8 [Build: 2	01808	10.15	1132]						
NeuroQ Version 3.x Neurological Application Software										
UDI: *+B133NEUROQ300/\$\$+73.8.201808104*										
Manufacturer Synterme 333 Sand Suite 107 Atlanta, G	: d, Inc. y Springs Circle NE A 30328 USA									
Support: Tel (Fax	888) 263-4446 ext. 1 : (888) 216-7511									
Authorized Re Medical Device Schiffgraben	epresentative: ce Safety Service GmbH (M 41, 30175 Hannover, Germa	IDSS) any								
	Display Manual									

d. Help – this option will
display the version number of
NeuroQ[™] and also shows the Unique
Device Identifier (UDI) information
for NeuroQ. The NeuroQ[™] User's
Manual can also be displayed in PDF
format by clicking the Display
Manual button.



R

2. Processing Menu – allows user to reformat the brain, the default number of iterations is 10 and that value will be used if the Reformat option is selected from the Processing drop down list. This processing step is described above in the Processing section.

> 3. Display Menu – the display menu allows you to display the Color Scale, display a list of region abbreviations, and hide/show patient information. The options are shown below.

CONFIDENTIAL

c: U

hys

May not be reproduced without written permission from Syntermed Inc. Reference SOP 8 (Drafting and approval of Labeling)



Page 19 of 45

NeuroQ User Manual



- b. "List Region Abbreviations" will list the various abbreviations used in the application along with their meaning, i.e. rAVC = right Associative Visual Cortex.
- c. "Hide Patient Information" will remove the patient identifiers from the screen (ie blank out the Patient Name, Hospital ID and Referring Physician).
- d. "Show Patient Information" will re-display the patient identifiers blanked out with "Hide Patient Information".
- 4. QC The Quality Control screen allows the user to apply some preprocessing steps including setting axial planes limits, removing scalp activity, and performing a rigid registration. See Quality Control section above for a further description.



5. Slices – When the Slices button is selected it will bring up a new display window which initially will display the patients transaxial slices. From the Slice Display menu item you can also select to display the sagittal or coronal slices. This display is shown below.



The initial display will show the patients slices in inverted grey scale. An option is provided to display other translation tables by clicking on the CM (Color Map) button located above the color translation bar.





A table of color translation options will be displayed shown in table to the left. You can select any of these color tables and the display will change to reflect this color.

Changing up/low contrast – At the top of the color bar on the slices page is a value of 100 and at the bottom a value of 0. If you position your cursor over one of these numbers, click left, hold down, and move the value up or down you can adjust the contrast in the image. The upper value (100) when moved down will lower the upper value producing a brighter image. The lower value

(0) when moved up will increase the lower value resulting in reducing counts in the image at the low end of the scale or darken the image.

You can display either the original images or images that have undergone registration from the Volume to Display drop down list. Note: to go back to the previous screen click on the Main button.

- 6. Compare The compare screen allows the user to compare two studies from the same patient performed at different times. This analysis provides a Difference Image between the two studies showing which regions showed a change in hypo or hyper metabolic activity between the two studies. See the description of the Compare feature below.
- PET/CT The PET/CT screen allows the user to display both the PET and CT studies for the same patient – and fuse those two data sets using scroll bars. See the description of the PET/CT feature below.
- 8. EQuAL The EQuAL analysis module is an optional feature that is helpful for evaluating temporal metabolic asymmetry. See the description of the EQuAL feature below for more information.
- 9. bgQ This is an analysis for DatScan.
- amyQ The amyQ analysis module is an optional feature that allows for the investigation of amyloid uptake in the brain. See the description of the Amyloid Analysis feature below for more information.
- 11. 3D This is a surface rendered 3D display that shows a template 3D brain along with the superimposed 47 brain clusters. The display consists of 12 static views of the brain and when one is selected it can be manually rotated. The cluster names can be displayed by rolling over the cluster with the mouse.
- 12. Save this option when selected will save all of the reformatted data and analysis into a single file called the NeuroQ[™] Review File. This file can then be selected and the previous reformatted data and analysis will be displayed. This avoids having to reformat the data if it needs to be displayed at another time.
- 13. Patient Information displays patient information.
- 14. Patient Brain Display displays the original patient brain transaxial slices.



- 15. Left Plane Slider controls the brain plane of the above patient brain display, the current plane number is displayed above the slider, slide to the left or right to access lower or higher planes respectively.
- 16. Normal Template Brain based on an archetypal normal brain with no clinical or metabolic signs of neurodegenerative disease; ROI values for each plane are drawn in with a white outline.
- 17. Middle Plane Slider controls the brain plane of the normal brain display and the reformatted patient brain display at right; the current plane number is displayed above the slider, slide to the left or right to access lower or higher planes respectively, simultaneously for both displays.
- 18. Reformatted Patient Brain brain is based on specified number of reiterations of the original patient brain scan; this display only appears after reiteration of brain images. All abnormal regions will be displayed in a two-dimensional coded color scale, click on the Help button for color coding explanation.
- 19. Table of Abnormal Regions displays all regions having internally normalized region of interest (ROI) radiotracer uptake values falling more than 1.65 standard deviations below the mean value (in the Hypometabolic operation) and more than 1.65 standard deviations above the mean value (in the Hypermetabolic operation) for a symptomatic control group; regions are displayed in abbreviated form with the plane number after the ".p"; the last row of the table gives a total of the "Pt-M(AC)" and "#SD from M(AC)" columns. By clicking on a hypometabolic region in the reformatted patient brain image, the name of the region will be displayed above the region table and the rwo of the region that was selected will be highlighted in the region table.
- 20. Table of Cluster Values the ROI cluster value is based on the average of the represented region across all planes where it is assessed. By clicking on one of the 47 cluster regions in the cluster screen, the name of the region will be displayed in the table below the cluster screen and the row of the region that was selected will be highlighted in the cluster table.





NeuroQ[™] Display Screen (Right Side)





1. Reference Region Menu – user can select which cluster (among "Pons", "Cerebellum", "Sensorimotor", "Thalamus", or "Whole Brain") to base the normalization of the regions on. NOTE: the default normalization is based on the whole brain.



2. Control Database – user can use this feature to create their own database to use within the NeuroQ[™] application. See description of this feature below.



3. Metabolism Menu – "Hypometabolism" displays the most hypometabolic regions and performs calculations accordingly, "Hypermetabolism" displays the most hypermetabolic regions and performs calculations accordingly, NOTE: default is "Hypometabolism".



- 4. Brain Plane Displays includes schematic display of each of the 47 ROI clusters, shown at the normal template planes numbered below each image. Refer to the "Show Color Scale" description for color coding explanation. Clicking on a ROI causes the full name and numerical characterization of that region to appear in the Data Display area.
- 5. Data Display displays information based on the last ROI cluster the user clicked on.
- 6. Regional and Cluster Data gives the most hypometabolic or hypermetabolic and most significant regions and clusters.



NeuroQ[™] Compare Display Screen

File Processing Display Side Display Reference Region Control Databases Metabolism Study Comparies EQuAL Patient Name: Neuro Q Study Compare 2001 Update Main QC Silces Compare PET/CT EQUAL bgQ amyQ 3D Save Baseline Study Date: 01-Jan-2001 C 2 2 3 20 22 Active Current Study Date: 01-Jan-2005 C 2 2 3 20 20 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 2 3 C 2 3 2 3 C 2 3 2 3 C 2 3 3 2 3 C 2 3 3 2 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 3 C 2 3 3 3 C 2 3 3 3 C 2 3 3 3 C 2 3 3 3 C 2 3 3 3 C 2 3 3 3 C 2 3 3 3 C 2 3 C 2 3 C 2 3 C 2 3 C 2 3 3 C 2 3 C 2 3 C 2 3 C 2 3 C 2 3 C 2 3 C 2 3 C 2 3 C 2 3

GIONAL AI SM.p9 (Diffe egion. SM.p9 (% D	ND CLUSTER D erence: -0.2426 ifference: -26.1	ATA 6) is the most 1964) is the r	Decreased egion with		1		6	223		Ľ	3	(2	60		
PCC (Differe cluster. PCC (% Diff	ence: -0.0955) erence: -8.254	is the most D 0) is the clus	ecreased ter with the		1	* 7		36		42		1	46		
-					_	ser.	Regional	Decreases:	ROI Name: Magnitude	of Difference:					
fference Re	gions:						Cluster Regi	ons:							
fference Re Region	gions: Mean AC	SD AC	Baseline (B)	Act\Cur (A)	A - B	%Diff((A-B)/B)	Cluster Region	Mean AC	SD AC	Baseline (B)	Act\Cur (A)	A - B	%Diff((A-B)/B		
fference Re Region rGFs.p32	gions: Mean AC 0.9708	SD AC 0.0756	Baseline (B) 1.2397	Act\Cur (A) 1.2017	A - B -0.0381	%Diff((A-B)/B)	Cluster Region Region rGFs	Mean AC	SD AC 0.0533	Baseline (B) 1.0461	Act\Cur (A) 1.0720	A - B 0.0259	%Diff((A-B)/B) 2.4772		
fference Re Region rGFs.p32 IGFm.p32	gions: Mean AC 0.9708 1.0079	SD AC 0.0756 0.0458	Baseline (B) 1.2397 1.2355	Act\Cur (A) 1.2017 1.1843	A - B -0.0381 -0.0512	%Diff((A-B)/B) -3.0717 -4.1436	Cluster Region Region rGFs rGFd	Mean AC 1.0094 1.0666	SD AC 0.0533 0.0375	Baseline (B) 1.0461 1.0925	Act\Cur (A) 1.0720 1.1117	A - B 0.0259 0.0192	%Diff((A-B)/B) 2.4772 1.7595	^	
fference Re Region rGFs.p32 IGFm.p32 IGFs.p32	gions: Mean AC 0.9708 1.0079 1.2465	SD AC 0.0756 0.0458 0.0444	Baseline (B) 1.2397 1.2355 1.1425	Act\Cur (A) 1.2017 1.1843 1.1168	A - B -0.0381 -0.0512 -0.0257	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530	Cluster Region Region rGFs rGFd IGFs	Mean AC 1.0094 1.0666 0.9778	SD AC 0.0533 0.0375 0.0481	Baseline (B) 1.0461 1.0925 1.0005	Act\Cur (A) 1.0720 1.1117 0.9713	A - B 0.0259 0.0192 -0.0291	%Diff((A-B)/B) 2.4772 1.7595 -2.9134	-	
fference Re Region rGFs.p32 IGFm.p32 IGFs.p32 IGFd.p32	egions: Mean AC 0.9708 1.0079 1.2465 1.1184 4.1202	SD AC 0.0756 0.0458 0.0444 0.0582	Baseline (B) 1.2397 1.2355 1.1425 1.1354 4.4220	Act\Cur (A) 1.2017 1.1843 1.1168 1.0899 4.0045	A - B -0.0381 -0.0512 -0.0257 -0.0455	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530 -4.0078	Cluster Region Region rGFs rGFd IGFs IGFd	Mean AC 1.0094 1.0666 0.9778 1.0552 1.0552	SD AC 0.0533 0.0375 0.0481 0.0347	Baseline (B) 1.0461 1.0925 1.0005 1.0586 4.0000	Act\Cur (A) 1.0720 1.1117 0.9713 1.0059	A - B 0.0259 0.0192 -0.0291 -0.0527	%Diff((A-B)/B) 2.4772 1.7595 -2.9134 -4.9824	^	
ifference Re Region rGFs.p32 IGFm.p32 IGFs.p32 IGFd.p32 rGFi.p32	egions: Mean AC 0.9708 1.0079 1.2465 1.1184 1.1303 4.9324	SD AC 0.0756 0.0458 0.0444 0.0582 0.0314	Baseline (B) 1.2397 1.2355 1.1425 1.1354 1.1220 4.0205	Act\Cur (A) 1.2017 1.1843 1.1168 1.0899 1.0946 0.0045	A - B -0.0381 -0.0512 -0.0257 -0.0455 -0.0274	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530 -4.0078 -2.4391 -2.5400	Cluster Region Region rGFs rGFd IGFs IGFd ISM	Mean AC 1.0094 1.0666 0.9778 1.0552 1.0612	SD AC 0.0533 0.0375 0.0481 0.0347 0.0422	Baseline (B) 1.0461 1.0925 1.0005 1.0586 1.0699 4.0699	Act\Cur (A) 1.0720 1.1117 0.9713 1.0059 1.0459	A - B 0.0259 0.0192 -0.0291 -0.0527 -0.0240	%Diff((A-B)/B) 2.4772 1.7595 -2.9134 -4.9824 -2.2442	^	
Ifference Re Region rGFs.p32 IGFm.p32 IGFs.p32 IGFd.p32 rGFa.p32 rGCa.p32	rgions: Mean AC 0.9708 1.0079 1.2465 1.1184 1.1303 1.0321 0.9905	SD AC 0.0756 0.0458 0.0444 0.0582 0.0314 0.0419 0.0948	Baseline (B) 1.2397 1.2355 1.1425 1.1354 1.1220 1.0205 1.4017	Act\Cur (A) 1.2017 1.1843 1.1168 1.0899 1.0946 0.9945 1.0602	A - B -0.0381 -0.0512 -0.0257 -0.0455 -0.0274 -0.0260 0.0515	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530 -4.0078 -2.4391 -2.5496 4.6752	Cluster Regin Region rGFs rGFd IGFs IGFd ISM rSM	Mean AC 1.0094 1.0666 0.9778 1.0552 1.0612 1.0442 0.0222	SD AC 0.0533 0.0375 0.0481 0.0347 0.0422 0.0332	Baseline (B) 1.0461 1.0925 1.0005 1.0586 1.0699 1.0590 0.0005	Act\Cur (A) 1.0720 1.1117 0.9713 1.0059 1.0459 1.0814 0.8220	A - B 0.0259 0.0192 -0.0291 -0.0527 -0.0240 0.0224	%Diff((A-B)/B) 2.4772 1.7595 -2.9134 -4.9824 -2.2442 2.1163 2.5222	^	
ifference Re Region rGFs.p32 IGFm.p32 IGFs.p32 IGFd.p32 rGFa.p32 IGCa.p32 IGCa.p32	gions: Mean AC 0.9708 1.0079 1.2465 1.1184 1.1303 1.0321 0.9995 1.0773	SD AC 0.0756 0.0458 0.0444 0.0582 0.0314 0.0314 0.0419 0.0948 0.0392	Baseline (B) 1.2397 1.2355 1.1425 1.1354 1.1220 1.0205 1.1017 1.1346	Act/Cur (A) 1.2017 1.1843 1.1168 1.0899 1.0946 0.9945 1.0502 1.0502	A - B -0.0381 -0.0512 -0.0257 -0.0455 -0.0274 -0.0260 -0.0515 0.0420	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530 -4.0078 -2.4391 -2.5496 -4.6753 3.7028	Cluster Regin rGFs rGFd IGFs IGFd ISM rSM IsPL rSM	Mean AC 1.0094 1.0666 0.9778 1.0552 1.0612 1.0442 0.9202 0.9696	SD AC 0.0533 0.0375 0.0481 0.0347 0.0422 0.0332 0.0472 0.0472	Baseline (B) 1.0461 1.0925 1.0005 1.0586 1.0699 1.0590 0.8925	Act/Cur (A) 1.0720 1.1117 0.9713 1.0059 1.0459 1.0814 0.8878 0.9692	A - B 0.0259 0.0192 -0.0291 -0.0527 -0.0240 0.0224 -0.0047	%Diff((A-B)/B) 2.4772 1.7595 -2.9134 -4.9824 -2.2442 2.1163 -0.5222 5.0023	^	
ifference Re Region rGFs.p32 IGFm.p32 IGFs.p32 IGFd.p32 rGFi.p32 rGCa.p32 ISLT.p32 IBLT.p32	gions: <u>Mean AC</u> 0.9708 1.0079 1.2465 1.1184 1.1303 1.0321 0.9995 1.0773 1.1323	SD AC 0.0756 0.0458 0.0444 0.0582 0.0314 0.0419 0.0948 0.0392 0.0529	Baseline (B) 1.2397 1.2355 1.1425 1.1354 1.1220 1.0205 1.1017 1.1346 1.0133	Act/Cur (A) 1.2017 1.1843 1.1168 1.0899 1.0946 0.9945 1.0502 1.0926 0.9391	A - B -0.0381 -0.0512 -0.0257 -0.0455 -0.0274 -0.0260 -0.0515 -0.0420 0.0742	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530 -4.0078 -2.4391 -2.5496 -4.6753 -3.7028 7.3333	Cluster Regin Region rGFs rGFd IGFd IGFs IGFd ISM rSM ISPL rSPL rSPL	Mean AC 1.0094 1.0666 0.9778 1.0552 1.0612 1.0442 0.9202 0.9696 1.1326	SD AC 0.0533 0.0375 0.0481 0.0347 0.0422 0.0332 0.0472 0.0462 0.0462	Baseline (B) 1.0461 1.0925 1.0005 1.0586 1.0590 0.8925 0.9138 1.160	Act/Cur (A) 1.0720 1.1117 0.9713 1.0059 1.0459 1.0814 0.8878 0.9603 1.1662	A - B 0.0259 0.0192 -0.0291 -0.0527 -0.0240 0.0224 -0.0047 0.0465 0.0202	%Diff((A-B)/B) 2.4772 1.7595 -2.9134 -4.9624 -2.2442 2.1163 -0.5222 5.0923 4.7704	^	
Region rGFs.p32 IGFm.p32 IGFs.p32 IGFd.p32 rGFd.p32 rGCa.p32 IGCa.p32 ISLT.p32 rTh.p32 rTh.p32	gions: Mean AC 0.9708 1.0079 1.2465 1.1184 1.1303 1.0321 0.9995 1.0773 1.0773 1.0452	SD AC 0.0756 0.0458 0.0444 0.0582 0.0314 0.0419 0.0948 0.0392 0.0529 0.0348	Baseline (B) 1.2397 1.2355 1.1425 1.1354 1.1220 1.0205 1.1017 1.1346 1.0133 1.0309	Act/Cur (A) 1.2017 1.1843 1.1168 1.0899 1.0946 0.9945 1.0502 1.0926 0.9391 1.0248	A - B -0.0381 -0.0512 -0.0257 -0.0455 -0.0274 -0.0260 -0.0515 -0.0420 -0.0742 -0.0742 -0.0742	%Diff((A-B)/B) -3.0717 -4.1436 -2.2530 -4.0078 -2.4391 -2.5496 -4.6753 -3.7028 -7.3233 -9.5822	Cluster Region Region rGFs rGFs IGFs IGFs IGFd ISM rSM ISPL rSPL rGFm	Mean AC 1.0094 1.0666 0.9778 1.0552 1.0612 1.0442 0.9202 0.9696 1.1236 1.1236 1.1236	SD AC 0.0533 0.0375 0.0481 0.0347 0.0422 0.0332 0.0472 0.0462 0.0313 0.0355	Baseline (B) 1.0461 1.0925 1.0005 1.0586 1.0590 0.8925 0.9138 1.1460 1.1460	Act/Cur (A) 1.0720 1.1117 0.9713 1.0059 1.0459 1.0814 0.8878 0.9603 1.1663 1.1420	A - B 0.0259 0.0192 -0.0291 -0.0527 -0.0240 0.0224 -0.0047 0.0465 0.0203	%Diff((A-B)/B) 2.4772 1.7595 -2.9134 -4.9924 2.1163 -0.5222 5.0923 1.7701 0.2244	^	

The NeuroQTM Compare Screen is enabled by selecting the two studies from the MCP screen and clicking on the launch button. Once NeuroQTM is launched it will show the most recent study in the main NeuroQTM screen. Click on the Compare button and the Compare display screen will be shown. The oldest study is displayed in the top row, the most recent in the middle row, and the difference image is displayed in the bottom image to the right. Use the middle slider bar in the middle row to step through the planes. All images with the exception of the patient's images in the left hand column will move when the slider bar is moved left or right. The difference image shows the regions in which there is at least a 1 standard deviation difference between the original and recent study. This analysis is helpful to monitor the progression of dementia over a period of time.



NeuroQ[™] PET/CT Display Screen



The PET/CT display allows for displaying both the PET and CT brain images from the same patient. The PET brain images are contained in the top row. The PET brain images brightness can be changed by sliding the PET Max Level slider up or down. The CT images are contained in the middle row. The CT brain images window level can be changed by manipulating the sliders for CT Level and CT Window up or down. The user also has the option picking preset windows for Neuro or Bone in the Preset Windows drop down box. The bottom row contains the fused images. The PET/CT slider bar allows the user to display only the PET (slider all the way up), only the CT (slider all the way down), or fused (slider in the middle). Various levels of fusion can be displayed by moving the slider up or down. Triangulation is enabled on the PET, CT and Fused images by clicking left on any image and it will show you the plane for that location on the other two images.



EQuALTM Analysis



Select the axial plane which visually demonstrates the greatest asymmetric difference in metabolic activity within the temporal cortex.

The Extent-Specified Quantified Asymmetry-of-Lobe (EQuAL) Analysis will be included with NeruoQ 3.0. This program is useful for assessing maximal temporal asymmetry over a specified proportion of the temporal lobe which may help to predict whether patients will likely be free of seizures during the years after neurosurgical resection of epileptogenic tissue.

To use EQuAL, select the patient desired and launch NeuroQTM from MCP. Process the study as you would normally. Once NeuroQTM is finished reformatting the data, select the EQuAL tab from the top of the screen. Select the image that the user feels best exemplifies the asymmetrical defect. Use the slider bar on the right hand side of the screen to see all slices. See example above.

Once an image has been selected, the EQuAL ROI screen will appear. Follow the on screen instructions to get the Asymmetry Index (AI).





EQuAL Processing – When processing an EQuAL study you are going to select an image from the above display and that is the image where an ROI over the temporal lobe will be drawn, as shown in the display below. When selecting that image you want to use the Assymetry Parameterized (AP) row of images (3rd and 6th row, images displayed in red) to select this image. You must see activity in the AP images in order for this analysis to provide valid data. A proper image would be image 36 shown with the circle drawn over the temporal lobe (remember you will be drawing your ROI on the gray scale images shown below). If you select images without activity (images 48 or 49 shown with arrows) then the values calculated will be 0. If the EQuAL value is 0, with the default extent specification of 20%, then first insure that there is visually evident bilateral asymmetry in the part of the brain over which the ROI has been drawn, and second, that the ROI has been placed on the side that has higher activity. If these 2 conditions have been met, then a 0 value indicates that fewer than 20% of the pixels in this ROI contribute to the observed asymmetry. To obtain a non-zero EQuAL value, try decreasing the extent specification to less than 20%.



File Processing Display Slice Display Reference Region Control Database Metabolism Study Comparison EQuAL EQuAL Patient Name: NeuroQ Demo (EQuAL) 00 Slices amyQ Data Main Save Help Study Date: 06-Jun-1996 Plane 37 Plane 34 Plane 35 Plane 36 Plane 38 0 1700 0 1874 0 1909 0 1356 0 1365 - Draw a ROI around the temporal cortex on the side showing the greatest level of asymmetry, using plane #: 36 Add point with left button region with right button the greatest level of asymmetry, using plane *H*: Jo Asymmetry index (A) loi sciculated and displayed below the images. The proportion of pixels to use for asymmetry calculation can be adjusted using the Extent Specification slider bar (20% was found to be optimal). The Al optimal range was found to be 0.19-0.40 for achieving post-aurgical Clear ROI 20 • seizure-free status

NeuroQ User Manual

The results of this study were by Lin et. al from the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA Los Angeles was published in the May issue of the Journal of Nuclear Medicine:

Tina W. Lin, Michelle A. Kung de Aburto, Magnus Dahlbom, Lynn L. Huang, Michael M. Marvi, Michael Tang, Johannes Czernin, Michael E. Phelps, and Daniel H.S. Silverman. Predicting Seizure-Free Status for Temporal Lobe Epilepsy Patients Undergoing Surgery: Prognostic Value of Quantifying Maximal Metabolic Asymmetry Extending over a Specified Proportion of the Temporal Lobe. J Nucl Med. 2007 48(5): 776-782.



Control Database

NeuroQTM provides the user with the ability to generate their own normal database to use within the application.

Reference Region	Con	trol Database	Metabolism	Study Com
ase3 Abn)		Select Databa	se	C
		Default FDG [Database	
Series Desc:		SPECT HMPA	O Database	ntrol a
Referring Phy		Create New D	atabase	staye
L	-	-		Я

- Select Database allows the user to select a database that was previously created by the user.
- Default FDG Database sets the PET FDG database that was created and validated by UCLA.
- SPECT HMPAO Database sets the SPECT HMPAO database that was created and validated by UCLA.
- Create New Database This allows the user to create their own normal database. The first step would be to process all of the normal studies through NeuroQTM and save them as NeuroQTM review files. These review files will have an extension .nrq. These NeuroQTM review files then need to be all placed in the same folder on the disk. After selecting Create New Database you will have to browse to the folder containing all of normal NeuroQTM Review files. After selecting that folder the following dialog screen is displayed.



Select the review files to include in the normal file						
Select All Files						
NeuroQ Demo (Case3 Abn) 2013-11-11 16:24:31 10 Iterations	NeuroQ Demo (Case3 Abn) 2013-11-11 16:24:31 10 Iterations					
NeuroQ Demo (Case3 Abn) 2014-11-18 09:25:38 10 Iterations	NeuroQ Demo (Case 3 Abn) 2014-11-18 09:25:38 10 Iterations					
FDGBrain 2008-08-11 09:59:13 20 Iterations	FDGBrain 2008-08-11 09:59:13 20 Iterations					
NeuroQ Study Compare 2001 2007-05-16 15:07:23 20 Iterations	NeuroQ Study Compare 2001 2007-05-16 15:07:23 20 Iterations					
NeuroQ Study Compare 2006 2007-05-16 15:03:34 20 Iterations						
□ NeuroQ Demo (Case3 Abn) 2010-08-25 22:56:04 20 Iterations	NeuroQ Demo (Case 3 Abn) 2010-08-25 22:56:04 20 Iterations					
NeuroQ Demo (PET/CT) 2007-05-15 17:15:50 20 Iterations						
No files selected						
Enter a name for the database:						
Cancel Create Database						

Select all the files you want included in the database, enter the name for the database file in the box, and then click on the Create DB button to generate the normal database. This normal file can then be selected and used as the normal database in NeuroQTM.

IMPORTANT: GENERATION OF A NORMAL DATABASE TO BE USED IN THE NEUROQ[™] APPLICATION IS THE SOLE RESPONSIBILITY OF THE USER. SYNTERMED OR UCLA HAVE ONLY VALIDATED THE PET FDG NORMAL DATABASE PROVIDED WITH THE APPLICATION. SYNTERMED AND UCLA HAVE NO RESPONSIBILITY OR ARE LIABLE FOR ANY RESULTS PROVIDED BY NEUROQ[™] THAT ARE GENERATED BY ANY OTHER DATABASE GENERATED BY USERS OF THE APPLICATION USING THIS TOOL.



Amyloid Overview, Processing, and Display

Introduction

The FDA approved the florbetapir F18 radiopharmaceutical agent (Trade name Amyvid, Eli Lilly) on April 6, 2012. Florbetapir binds to amyloid aggregates in the brain, and the florbetapir PET image is used to estimate the density of β -amyloid neuritic plaque (17).

Florbetaben, a fluorine-18 (18F)-labeled stilbene derivative, trade name NeuraCeq (Piramal), is a diagnostic radiopharmaceutical developed for routine clinical application to visualize β -amyloid plaques in the brain. The FDA approved NeuraCeq in 2014.

Flutemetamol, a fluorine-18 (18F), is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. Trade name Vizamyl and FDA approved in 2013.

Image Registration and Development

The amyloid image registration is performed in two parts. First the subject's brain is aligned to the reference brain using a rigid registration (i.e., translations in x, y and z, and rotations around the three axes). The maximization of the mutual information is the metric used to determine the best registration parameter. The result from the rigid registration is then passed onto a B-spline based deformable image registration algorithm, which also attempts to maximize the mutual information between the two image volumes to determine the best registration. For computational efficiency and faster convergence, the deformable registration is performed in two parts. First, using a coarse grid, which is followed by a registration using a finer and more precise grid.

In addition to the development of the registration software, a template or reference amyloid brain was constructed, which is used when analyzing individual amyloid images. For this, 20 with low uptake of amyloid in PET studies were selected. Each one of these subjects also had anatomical images (i.e., T1 weighted MRI). Using the high-resolution anatomical imaging for registration allows for a more accurate registration compared to a PET-to-PET registration. The subject's PET was first registered to the MRI. Then the MRI was registered to the reference brain template, already defined in NeuroQ for the analysis of FDG brain images. The registration performed was the same as described above (i.e., rigid registration followed by a deformable registration). Once the transformation of the subject's MRI to the reference template was found, the same transformation was applied to the subject's amyloid PET image.

This process was repeated for all 20 low amyloid uptake subjects. Each registered PET study was then normalized to the average uptake in cerebellum. The amyloid reference brain was finally constructed by taking the average of all 20 registered and normalized brains. In the analysis of a subject's amyloid images, the PET images are first registered to the reference amyloid brain, using the registration method described.

Following the registration, the average uptake in the cortex and in cerebellum is determined. These regions are a subset of the regions already defined in the brain template in NeuroQ. The



ratio of the average cortex uptake to the average uptake in cerebellum is then calculated. This ratio value has been integrated into the current NeuroQ application (18) and displayed together with a visualization of the regions used in the determination of the uptake in cortex and cerebellum, overlaid on the subjects registered brain. The output for the Amyvid (Lilly) analysis is shown in Figure 1 and NeuraCeq (Piramal) in Figure 2. Vizamyl (GE) is under development.

When the initial amyloid study is brought into NeuroQ and the amyQ button is selected the user will be presented with a dropdown box and the agent being used should be selected from the list. The dropdown list is shown below.



Amyloid processing

The steps for processing an amyloid study are listed below.

- 1. Select the amyloid study from the MCP screen and launch into the NeuroQ application.
- 2. Click on the amyQ button and select the amyloid agent used for the study. The processing is automatic and will initiate once the agent is selected
- 3. Once the processing is completed the amyloid analysis window will be displayed showing the patients results (Fig 1/Fig 2).

PLEASE NOTE: The ratios of overall cortex to cerebellum is provided as a general index of the magnitude of cortical tracer retention only. There are no recognized or intended threshold values for drawing specific conclusions about an individual patient's diagnosis or prognosis.

The relative patterns of distribution of tracer retention within the cortex, as illustrated by the color-coded displays of regional distribution, are intended to be used as an adjunct to visual analysis, which the user can employ for the purpose of indicating specific regions upon which extra attention may be focused in carrying out visual interpretations.



Amyvid Analysis



Figure 1 - Amyloid Analysis Display Output. The display output of the amyloid analysis in the NeuroQ application is shown. The regions representing the cortex (white matter) are shown in shades of red/purple and the cerebellum (gray matter) are shown in blue. The ratio between the cortex and cerebellum is calculated and shown on the display output, in this case the ratio was calculated as 1.656. Clicking on the Show ROIs button will bring up a display of the ROIs used in this analysis.

Validation

The results of the validation conducted for the amyloid study using this technique demonstrated the following with respect to the cortex vs cerebellum average ratio: low amyloid uptake (n=80), mean = 0.988 ± 0.058 and high amyloid uptake (n=39), mean= 1.504 ± 0.192 . Using a ratio cutoff of 1.10 the results for detecting high levels of amyloid in the high amyloid uptake group was 20/20 and for detecting low levels of amyloid in the low amyloid uptake group was 19/20.



NeuraCeq Analysis



Figure 2 - NeuraCeq Analysis Display Output. The display output of the amyloid analysis using NeuraCeq in the NeuroQ application is shown. The regions representing the cortex (white matter) are shown in shades of red/purple and the cerebellum (gray matter) are shown in blue. The ratio between the cortex and cerebellum is calculated and shown on the display output, in this case the ratio was calculated as 1.577. Clicking on the Show ROIs button will bring up a display of the ROIs used in this analysis.

Validation

The results of the NeuraCeq validation conducted for the amyloid study using this technique demonstrated the following with respect to the cortex vs cerebellum average ratio: low amyloid uptake (n=61), mean = 1.198 ± 0.115 and high amyloid uptake (n=61), mean= 1.590 ± 0.243 . Using a ratio cutoff of 1.31 the results for detecting high levels of amyloid in the high amyloid uptake group was 55/61 (90%) and for detecting low levels of amyloid in the low amyloid uptake group was 56/61 (92%).





SPECT Overview, Processing and Display

Introduction

The NeuroQ application can also be used to process HMPAO SPECT brain studies.

Image Processing

1. Database in Use

The database used for analysis of SPECT studies should be the SPECT HMPAO Database. The NeuroQ program attempts to determine if this is a SPECT study when you first launch NeuroQ with a SPECT study. If this database is not displayed as the Database in use then you will need to go to Control Database menu item and select the proper normal database for the patient.



2. Quality Control Screen

The first screen displayed is the Quality Control Screen. The only option is "Reformat SPECT" which automatically does all of the necessary processing to compare this patient to the SPECT normal file..



File Processing Display Slice Display Reference Region Control Database Activity Study Comparison EQuAL Patient Name: SPECT Abnormal Main QC Slices Compare PET/CT EQuAL amyQ Data Save Help Study Date: 04-Apr-2014 Database in use: SPECT HMPAO Database **Rigid Registration** Reference -Blend Original 💌 Reformat SPECT C Accept

NeuroQ User Manual

3. Reformatting

Click on the Reformat SPECT button and the following notification screen will be displayed letting you know that 10 iterations will be used for the reformatting. Next select the OK button to start the reformatting process.

	NeuroQ™ Information	Original	
đ	You have chosen to reformat a SPECT study. This process may take a while. Please be patient.		
1	OK Cancel	Realigned and Fused 50	Þ
	Reference 💌	Blend	Original 💌
		Rigid Registration	
		Reformat SPECT	

4. Further Processing

The remainder of the processing and display is the same for FDG and SPECT and this is described above in the section titled NeuroQ Analysis Screen on pages 11 - 17.



3D Display

Overview

The NeuroQ application can display surface rendered images in 3D with the 47 ROI clusters integrated into the display. Click right on any image and it will be displayed in the center of the image and you will be able to manually rotate the image (click left, hold and move). If you hover the mouse over any of the 47 clusters then the name, Pt-M(AC), and #SD from M(AC) values will be displayed at the bottom left of the image.



The zoomed image that can be manually rotated is shown below.

Page 38 of 45







Analysis of Basal Ganglia Structures

Introduction

An algorithm was developed and implemented into NeuroQ to semi-automatically analyze radiotracer uptake data in basal ganglia structures. As seen in Figure 1, the user can choose a plane where the basal ganglia are most pronounced and can overlay a predefined set of ROIs over the right and left sets of regions. The program takes the maximal activity along a line spanning the three outlined structures that comprise the basal ganglia (caudate head, anterior putamen, and posterior putamen). To account for variations in the plane chosen, the average value of the maximal activity on the planes spanning from two below to two above the user's chosen one are calculated relative to the superior occipital cortical activity and output is entered into a table that separates the uptake values by region and cerebral hemisphere.

Validation

Normal limits were established in 35 patients that without reduced dopamine transporter radiotracer (DaTscanTM). Validation of this program was performed by running scans of 54 patients referred for evaluation of motor symptoms. Twenty-one of these patients had reduced dopamine transporter radiotracer (DaTscanTM), but were considered normal by basal ganglia imaging criteria according to interpretation by the experienced readers and long-term follow up, while 33 were positive with reduced dopamine transporter radiotracer (DaTscanTM), by clinical follow up and/or 100% concordance among three to four visual interpreters, at least two separate institutions.

Two tables one reporting the values of right and left caudate head, anterior putamen, posterior putamen, as well as ratios of posterior putamen to anterior putamen, posterior putamen to caudate head, and anterior putamen to caudate head (see Figures 1 and 2), and another listing means and SD's of the values for the normal subjects are provided (Figure 3).

Statistical analysis:

Mean, standard deviation, and standard error of the mean were calculated for radiotracer uptake in the structures and uptake ratios described above, for normal and PD patient groups for each user. A two-tailed t-test was performed to test for significant differences between users. Inter-rater concordance rates, intra-rater concordance rates for user operating two independent workstations, and sensitivity and specificity values for the automated NeuroQ output versus the conventional scan interpretation were also calculated for the 6 sub regions and 6 corresponding regional ratios.



Results:

Inter-observer reproducibility was highly significant, even between trainee interpreters using the module for quantifying basal ganglia sub regions (e.g., ratios of right posterior putamen to right anterior putamen Pearson coefficient r=0.59, p=0.00002; ratios of left posterior putamen to left anterior putamen r=0.78, p<0.00001)

Guided by the mean \pm SD values of the sub regions and ratios of normal scans, it was found that the most diagnostically relevant ratio – activities in posterior putamen to superior occipital cortex - fell below the normal range (at least -2.0 SD lower than normal mean) in 91% of the cases with reduced dopamine transporter radiotracer (DaTscanTM), and only in 9.5% of the cases without reduced dopamine transporter radiotracer (DaTscanTM)... that is, sensitivity, specificity, and overall accuracy of quantification-based dichotomized interpretations were all at least 90%.



Figure 1: Display output





Structure	Right	Left
Caudate	3.32	2.96
Ant. Putamen	3.72	2.70
Post. Putamen	2.60	2.44
Ant. Putamen/Caudate	1.12	0.91
Post. Putamen/Ant. Putamen	0.70	0.90
Post. Putamen/Caudate	0.78	0.82

Figure 2: Positive Patient Study (Pt233, SDx2)



	Right	Left
Caudate	4.46	4.88
Ant. Putamen	3.97	5.25
Post. Putamen	3.72	3.18
Ant. Putamen/Caudate	0.89	1.08
Post. Putamen/Ant. Putamen	0.94	0.61
Post. Putamen/Caudate	0.83	0.65

Figure 3: Negative Patient Study (Pt206, SDx2)

Structure	Mean	±1 SD	Lower Limit of Normal (Mean-2SD)
rCaudate	5.18	±1.11	2.96
lCaudate	5.41	± 1.08	3.26
rPutamen(Ant)	5.88	±1.23	3.43
rPutamen(Post)	4.47	±1.05	2.38
lPutamen(Ant)	5.80	±1.28	3.24



Ratios			
Structure	Mean	±1 SD	Lower Limit of Normal (Mean-2SD)
Post/Ant Putamen Right	0.76	±0.10	0.56
Post/Ant Putamen Left	0.74	±0.10	0.55
Post Putamen/r.Caudate	0.87	±0.14	0.60
Post.Putamen/I.Caudate	0.80	±0.11	0.58
Ant.Putamen/r.Caudate	1.14	±0.10	0.94
Ant.Putamen/l.Caudate	1.07	±0.12	0.83

Figure 4: Normal Range for Regions and Ratios

Validation:

E1 unambiguous visual and/or confirming clinical follow up				
	(+)	(-)		
(+)	30	2	PPV = 94%	
(-)	3	19	NPV = 86%	
	Sensitivity = 91%	Specificity = 90.5%		

Table 1: Sensitivity/Specificity

Processing the basal ganglia study

- 1. Select a brain study and launch into the NeuroQ application.
- 2. Click on the bgQ button
- 3. The 5 brain slices displaying the basal ganglia are displayed. You can move the slices left or right with the slider bar to select the appropriate slices demonstrating the basal ganglia in all 5 views.
- 4. The left and right regions can be moved if not in the correct location.
- 5. The program automatically calculates the ROI values and displays them in a table below the images as shown in Figure 1.



References Related to NeuroQTM Development

Book

1. Daniel Silverman. **PET in the Evaluation of Alzheimers Disease and Related Disorders.** Springer Publishing, 2009. Chapter 7- Interpretive Practice Atlas, contains 19 case studies where the NeuroQ output is used to demonstrate how the quantitation is integrated into the process to improve the interpretation of the patient's brain study.

Publications

- 2. Silverman DH. Brain F18-FDG PET in the Diagnosis of Neurodegenerative Dememtias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging. J Nucl Med 2004; 45:594-607,
- TW Lin, MA Kung de Aburto, M Dahlbom, LL Huang, MM Marvi, M Tang, J Czernin, ME Phelps, and DHS Silverman. "Predicting Seizure-Free Status for Temporal Lobe Epilepsy Patients Undergoing Surgery: Prognostic Value of Quantifying Maximal Metabolic Asymmetry Extending over a Specified Proportion of the Temporal Lobe". J Nucl Med. 2007 48(5): 776-782
- 4. Nare Torosyan, Kelsey Mason, Magnus Dahlbom, Daniel Silverman, the Alzheimer's Diesease NeuroImaging Initiative. "Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. Eur J Nucl Med Mol Imaging. March 2017.
- Silverman DH, Devous MD. PET and SPECT imaging in evaluating Alzheimer's disease and related dementia. In: Ell PJ, Gambhir SS, eds. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. New York: Churchill Livingstone, 2004:1435-1473.
- 6. Gholam Berenji, Yuxin Li, Christian Carter, Daniel Silverman, Li-Jung Liang and Suzie El-Saden: "FDG PET in traumatic brain injury". J Nucl Med. 2010; 51 (Supplement 2):1814
- 7. Silverman DH, Devous MD. PET and SPECT imaging in evaluating Alzheimer's disease and related dementia. In: Ell PJ, Gambhir SS, eds. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. New York: Churchill Livingstone, 2004:1435-1473.
- Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging 1999;2:119-130.
- 9. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;268:2120-2127.
- Silverman DHS, Phelps ME, Application of positron emission tomography to evaluation of metabolism and blood flow in human brain: normal development, aging, dementia and stroke. *Molec. Genetics andMetab.* 74:128-138, 2001.
- 11. Silverman D.H.S., Lu CS., Wong G.R., Aung A.M.K., Czemin J., Phelps M.E., Small G.W., Dahlbom M. Comparison of methods for comparing brain images of individual cognitively impaired patients to a normal group. *Journal of Nuclear Medicine*, 42(suppl):224P, 2001
- 12. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594-607.
- 13. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for AD. Proc Nat Acad Sci U S A 2000;97:6037-6042.
- 14. Silverman DH, Truong CT, Kim SK, et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 2003;80:350-355.
- 15. Hoffman JM, Hanson MW, Welsh KA, et al. Interpretation variability of 18FDG-positron emission tomography studies in dementia. Invest Radiol 1996;31:316-322.
- 16. Silverman DH, Mosconi L, Ercoli L, et al. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 2008;38:251-61.



- 17. Silverman DHS and Melega WP, Molecular imaging of biological processes with PET: evaluating biologic bases of cerebral function, in *PET: Molecular Imaging and Its Biological Applications*, pp. 509-583, Springer-Verlag, New York, 2004.
- Minoshima, Satoshi, Frey, Kirk A., Koeppe, Robert A., Foster, Norman L., and Kuhl, David E., A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. *Journal of Nuclear Medicine*, 36: 1238-1248, 1995.
- 19. Tai, Y.-C., Lin, K.-P., Hoh, C.K., Huang, S.-C., Hoffman, E.J., Utilization of 3-D Elastic Transformation in Registration of Chest X-ray CT and Whole Body PET. *IEEE Trans. Nucl. Sci. NS-44* **4**: 1606-1612, 1997.
- Minoshima, S., K.A. Frey, J.H. Burdette, T. Vander Borght, R.A. Koeppe, D.E. Kuhl, Interpretation of metabolic abnormalities in Alzheimer's disease using three-dimensional stereotactic surface projections (3D-SSP) and normal database. *Journal of Nuclear Medicine*. 36:237P, 1995.
- Ishii, K., Sakamoto, S., Sasaki, M., Kitagaki, H., Yamaji, S., Hashimoto, M., Imamura, T., Shimomura, T., Hirono, N., Mori, E., Cerebral glucose metabolism in patients with frontotemporal dementia. *J. Nucl. Medicine.* 39:1875-1878, 1998.
- Silverman D.H.S., Marseille D.M., Peng N.X., Dahlbom M., Small G.W., Chen W., Czernin J., Phelps M.E. Comparing brain PET scans of individuals undergoing dementia evaluation to co-registered normal databases: effect of varying how "Normal" is defined. *Journal of Nuclear Medicine*, 44(suppl):17P, 2003.
- 23. Minoshima S, Giordani B, Berent S, Frey K Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. *Ann Neurol* 1997; 42:85-94.
- 24. Silverman DHS, Gambhir SS, Huang HWC, Schwimmer J, Kim S, Small GW, Chodosh J, Czernin J, Phelps ME Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. *J Nucl Med.* 2002; 43:253-266.
- 25. Silverman DHS and Alavi A, PET imaging in the assessment of normal and impaired cognitive function. *Radiologic Clin North Am* Saunders/Elsevier, Philadelphia, 2005;43:67-77.
- Moulin-Romsee G, Maes A, Silverman D, Mortelmans L, Van Laere K. (2005) Cost-effectiveness of 18Ffluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. *Eur J Neurol.* 12:254-263.
- 27. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Using positron emission tomography and florbetapir f 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. *Arch Neurol.* 2011; 68:1404-1411.
- 28. Silverman DHS, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, Czernin J, et al. Positron emission Silverman, D.H.S., Lu C.S., Wong G.R., Aung A.M.K., Czernin J., Phelps M.E., Small G.W., Dahlbom M. (2000) Development of standardized region of interest software for prognostic evaluation of early dementia. *Proc of the Intl Conf on Mathematics and Engineering Techniques in Med and Biol Sci*, 2:428.
- 29. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. *Alzheimers Dement*. 2011 Oct 31. [Epub ahead of print]
- Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. *Alzheimers Dement*. 2010; 6:221-9. PubMed Central PMCID: PMC2920531.